This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The young people who wanted to quit e-cigarettes didn’t necessarily think they were addicted. But they did think nicotine cravings were a problem. When they enrolled in a Massachusetts General Hospital trial, they told researchers they couldn’t study in the library or work at their desks for long before getting the urge to vape. “They really didn’t like that loss of control,” said Eden Evins, director of the addiction center at Mass General.
Dual immunotherapy, a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), has been granted extension in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA), and recommended by the National Institute for Health and Care Excellence (NICE). It is now a treatment option via NHS-funded commissioning, marking a major milestone for treating patients with […] The post Dual immunotherapy for bowel cancer now available under NHS appeared first on Pharmafile.
Amid ongoing battles over alternate supplies of blockbuster weight loss drugs, Eli Lilly filed new lawsuits against four telehealth firms and their affiliates, but is using a new line of attack — the drugmaker accused two of the companies of engaging in the corporate practice of medicine. To date, Lilly and its rival, Novo Nordisk, have filed dozens of suits against numerous companies involved in compounding versions of semaglutide and tirzepatide, the obesity and diabetes drugs known as
Effective from September 2025, AOTIs Topical Wound Oxygen (TWO2) therapy has been awarded inclusion in the NHS supply chain. It treats diabetic foot ulcer (DFU) and significantly lowers overall diabetic foot care costs. This adoption follows the publication of results from a health economic (HE) study in the Journal of Diabetic Complications that demonstrated that the […] The post AOTI diabetic foot care therapy to be used by NHS appeared first on Pharmafile.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
When a person with dementia gets something fundamental wrong — the year it is, your relationship to them — it can be difficult to know what to do. Do you correct them and risk upsetting them? Is it a lie or unethical to go along with it? Ted Johnson, who chairs the Department of Family and Preventive Medicine at the Emory School of Medicine, says that playing along is not only OK; it’s often the best thing for both the patient and the caretaker.
Swiss pharma manufacturing company, CARBOGEN AMCIS, has announced that its facility in Shanghai, China, has been successfully granted Drug Manufacturing License (DML) from Chinas National Medical Products Administration (NMPA). This marks a significant step in the companys expansion into the Chinese pharma market. The Shanghai site excelled in all regulatory expectations when good manufacturing practices(GMP) […] The post CARBOGEN AMCIS manufacturing license advances services in China appe
It starts with the ticks. These insects infect people with the bacteria that cause Lyme disease, microbes that are complicated to study, difficult to detect when they cause illness, and challenging to treat so they don’t linger in the human body. Understanding that bacterium, Borrelia burgdorferi, requires basic research before creating diagnostics or vaccines, slow progress that is frustrating for people affected by the chronic fatigue and brain fog of long-term Lyme disease or the joint
It starts with the ticks. These insects infect people with the bacteria that cause Lyme disease, microbes that are complicated to study, difficult to detect when they cause illness, and challenging to treat so they don’t linger in the human body. Understanding that bacterium, Borrelia burgdorferi, requires basic research before creating diagnostics or vaccines, slow progress that is frustrating for people affected by the chronic fatigue and brain fog of long-term Lyme disease or the joint
Introduction In 2025, the pharmaceutical industry finds itself in the midst of a digital transformation, where trust and personalization are more important than ever. Pharma brands are no longer competing solely on productstheyre competing on relationships. As a result, customer engagement strategies have taken center stage in shaping how companies connect with healthcare professionals (HCPs), patients, caregivers, and stakeholders.
Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it this far, so we are determined to hang on for another couple of days. And why not? The alternatives — at least those we can identify — are not particularly appealing, as you might imagine.
Boehringer Ingelheim and Tessellate Bio have agreed to develop first-in-class, oral precision treatments for alternative lengthening of telomeres (ALT) ALT positive cancers. The research collaboration and global license agreement, Tessellate Bios first pharma collaboration, is valued in excess of 500 million. The firm is eligible for near term and milestone payments, subject to market success.
WASHINGTON — The health official who helped convince President Trump during his first term that it’s possible to end the HIV epidemic in the United States is now imploring the president to stay the course, as funding cuts threaten to undo progress toward curbing the virus. “Trump ’47 should not allow Trump ’45’s massive public health achievement to be cancelled — especially when that legacy will be remembered in history books as the be
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Y ou’re reading the web edition of STAT’s AI Prognosis newsletter, our subscriber-exclusive guide to artificial intelligence in health care and medicine. Sign up to get it delivered in your inbox every Wednesday. We’re going to dive into a wonky one today. As Ms. Frizzle would say , “Seatbelts, everyone!
Researchers explored whether or not hormonal contraceptive initiation is associated with increased risk of developing depression within 12 months of child delivery.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. It’s been one year since I began co-authoring this newsletter! It’s been a great time bringing you biotech news every week, and please continue to send any ideas and tips my way: elaine.chen@statnews.com.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Expert in drug markets, Luke Turnock, PhD, joined Drug Topics to assess where he thinks recent trends in drug advertising will lead patients in the near-to-long-term future.
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Hey all, it’s Lev Facher again. It’s late April, which means it’s already STAT Wunderkinds season! This is your chance to nominate your favorite accomplished, motivated early-career researcher for nationwide recognition.
New research highlights the long-lasting effectiveness of mRNA COVID-19 vaccines, showing sustained B-cell and antibody responses in health care workers over 3 years.
One of the biggest congressional battles this year will be an upcoming reconciliation bill, which could see the Medicaid program cut by hundreds of billions of dollars. Here's how that could impact the country's healthcare system.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
NIH Director Dr. Jay Bhattacharya told advisers on Monday that the agency would create a central platform of patient records to aid autism research, in line with the goals of Health Secretary RFK Jr.
Blue Shield of California shared members' private health information with Google over a nearly three-year period, the insurance giant revealed earlier this month.
Axtria Inc., an AI-first data analytics innovator and global provider of cloud software to the life sciences industry, today announced its next generation of Axtria InsightsMAx, powered by agentic AI.
Ronna Hauser, PharmD, senior vice president of policy and pharmacy affairs at NCPA, discussed concerns the association has with the implementation of the Medicare Drug Price Negotiation Plan
Joydeep Ganguly, SVP, corporate operations, interim CIO, Gilead Sciences, shares how stakeholders can drive meaningful, lasting impact by turning pledges into proof points, exercising patience, and embedding sustainability into core business operations.
Input your email to sign up, or if you already have an account, log in here!
Enter your email address to reset your password. A temporary password will be e‑mailed to you.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content